Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program

Jonathan Krakoff, Jeanne M. Clark, Jill P. Crandall, Charlton Wilson, Mark E. Molitch, Frederick L. Brancati, Sharon L. Edelstein, William C. Knowler

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and impaired glucose tolerance. We investigated whether metformin or changes in metabolic measurements (weight, fasting plasma glucose (FPG), or fasting insulin (FI)) improved serum alanine aminotransferase (ALT) activity, as a marker for NAFLD, in the Diabetes Prevention Program (DPP). From 1996 to 1999, 2,153 participants without marked elevations of serum ALT at baseline were randomized (1,081 to placebo, 1,072 to metformin) and treated for an average of 3.2 years. ALT increased during the first 2 years of the study, and was slightly but significantly lower in the participants randomized to metformin. In regression models adjusted for sex, baseline age, FPG, and FI, these differences remained significant, but disappeared after adjustment for weight, FPG, and FI changes at each examination. The 3-year cumulative incidence for development of abnormal ALT concentrations was not significantly different ((mean s.e.) 21.4 1.4% and 24.6 1.4%, P = 0.11) in the metformin vs. placebo groups but was lower in individuals in both groups that lost more weight by the end of year 1 (metformin: 19.4 2.4% vs. 27.5 3.7%, for highest vs. lowest quartile of weight loss; placebo: 18.7 3.4% vs. 28.8 2.6%). Over 3 years of follow-up in persons at high risk for development of diabetes, serum ALT was consistently lower in those treated with metformin compared with placebo. This effect was mediated by weight loss, indicating that the effects of metformin therapy on ALT is via its effects on weight.

Original languageEnglish (US)
Pages (from-to)1762-1767
Number of pages6
JournalObesity
Volume18
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Metformin
Alanine Transaminase
Weight Loss
Fasting
Serum
Placebos
Weights and Measures
Insulin
Glucose
Glucose Intolerance
Insulin Resistance
Obesity
Incidence

ASJC Scopus subject areas

  • Endocrinology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Krakoff, J., Clark, J. M., Crandall, J. P., Wilson, C., Molitch, M. E., Brancati, F. L., ... Knowler, W. C. (2010). Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity, 18(9), 1762-1767. https://doi.org/10.1038/oby.2010.21

Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. / Krakoff, Jonathan; Clark, Jeanne M.; Crandall, Jill P.; Wilson, Charlton; Molitch, Mark E.; Brancati, Frederick L.; Edelstein, Sharon L.; Knowler, William C.

In: Obesity, Vol. 18, No. 9, 09.2010, p. 1762-1767.

Research output: Contribution to journalArticle

Krakoff, J, Clark, JM, Crandall, JP, Wilson, C, Molitch, ME, Brancati, FL, Edelstein, SL & Knowler, WC 2010, 'Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program', Obesity, vol. 18, no. 9, pp. 1762-1767. https://doi.org/10.1038/oby.2010.21
Krakoff, Jonathan ; Clark, Jeanne M. ; Crandall, Jill P. ; Wilson, Charlton ; Molitch, Mark E. ; Brancati, Frederick L. ; Edelstein, Sharon L. ; Knowler, William C. / Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. In: Obesity. 2010 ; Vol. 18, No. 9. pp. 1762-1767.
@article{c7cbe0faa2cf43c3aac8c33ee27d2620,
title = "Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program",
abstract = "Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and impaired glucose tolerance. We investigated whether metformin or changes in metabolic measurements (weight, fasting plasma glucose (FPG), or fasting insulin (FI)) improved serum alanine aminotransferase (ALT) activity, as a marker for NAFLD, in the Diabetes Prevention Program (DPP). From 1996 to 1999, 2,153 participants without marked elevations of serum ALT at baseline were randomized (1,081 to placebo, 1,072 to metformin) and treated for an average of 3.2 years. ALT increased during the first 2 years of the study, and was slightly but significantly lower in the participants randomized to metformin. In regression models adjusted for sex, baseline age, FPG, and FI, these differences remained significant, but disappeared after adjustment for weight, FPG, and FI changes at each examination. The 3-year cumulative incidence for development of abnormal ALT concentrations was not significantly different ((mean s.e.) 21.4 1.4{\%} and 24.6 1.4{\%}, P = 0.11) in the metformin vs. placebo groups but was lower in individuals in both groups that lost more weight by the end of year 1 (metformin: 19.4 2.4{\%} vs. 27.5 3.7{\%}, for highest vs. lowest quartile of weight loss; placebo: 18.7 3.4{\%} vs. 28.8 2.6{\%}). Over 3 years of follow-up in persons at high risk for development of diabetes, serum ALT was consistently lower in those treated with metformin compared with placebo. This effect was mediated by weight loss, indicating that the effects of metformin therapy on ALT is via its effects on weight.",
author = "Jonathan Krakoff and Clark, {Jeanne M.} and Crandall, {Jill P.} and Charlton Wilson and Molitch, {Mark E.} and Brancati, {Frederick L.} and Edelstein, {Sharon L.} and Knowler, {William C.}",
year = "2010",
month = "9",
doi = "10.1038/oby.2010.21",
language = "English (US)",
volume = "18",
pages = "1762--1767",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program

AU - Krakoff, Jonathan

AU - Clark, Jeanne M.

AU - Crandall, Jill P.

AU - Wilson, Charlton

AU - Molitch, Mark E.

AU - Brancati, Frederick L.

AU - Edelstein, Sharon L.

AU - Knowler, William C.

PY - 2010/9

Y1 - 2010/9

N2 - Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and impaired glucose tolerance. We investigated whether metformin or changes in metabolic measurements (weight, fasting plasma glucose (FPG), or fasting insulin (FI)) improved serum alanine aminotransferase (ALT) activity, as a marker for NAFLD, in the Diabetes Prevention Program (DPP). From 1996 to 1999, 2,153 participants without marked elevations of serum ALT at baseline were randomized (1,081 to placebo, 1,072 to metformin) and treated for an average of 3.2 years. ALT increased during the first 2 years of the study, and was slightly but significantly lower in the participants randomized to metformin. In regression models adjusted for sex, baseline age, FPG, and FI, these differences remained significant, but disappeared after adjustment for weight, FPG, and FI changes at each examination. The 3-year cumulative incidence for development of abnormal ALT concentrations was not significantly different ((mean s.e.) 21.4 1.4% and 24.6 1.4%, P = 0.11) in the metformin vs. placebo groups but was lower in individuals in both groups that lost more weight by the end of year 1 (metformin: 19.4 2.4% vs. 27.5 3.7%, for highest vs. lowest quartile of weight loss; placebo: 18.7 3.4% vs. 28.8 2.6%). Over 3 years of follow-up in persons at high risk for development of diabetes, serum ALT was consistently lower in those treated with metformin compared with placebo. This effect was mediated by weight loss, indicating that the effects of metformin therapy on ALT is via its effects on weight.

AB - Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and impaired glucose tolerance. We investigated whether metformin or changes in metabolic measurements (weight, fasting plasma glucose (FPG), or fasting insulin (FI)) improved serum alanine aminotransferase (ALT) activity, as a marker for NAFLD, in the Diabetes Prevention Program (DPP). From 1996 to 1999, 2,153 participants without marked elevations of serum ALT at baseline were randomized (1,081 to placebo, 1,072 to metformin) and treated for an average of 3.2 years. ALT increased during the first 2 years of the study, and was slightly but significantly lower in the participants randomized to metformin. In regression models adjusted for sex, baseline age, FPG, and FI, these differences remained significant, but disappeared after adjustment for weight, FPG, and FI changes at each examination. The 3-year cumulative incidence for development of abnormal ALT concentrations was not significantly different ((mean s.e.) 21.4 1.4% and 24.6 1.4%, P = 0.11) in the metformin vs. placebo groups but was lower in individuals in both groups that lost more weight by the end of year 1 (metformin: 19.4 2.4% vs. 27.5 3.7%, for highest vs. lowest quartile of weight loss; placebo: 18.7 3.4% vs. 28.8 2.6%). Over 3 years of follow-up in persons at high risk for development of diabetes, serum ALT was consistently lower in those treated with metformin compared with placebo. This effect was mediated by weight loss, indicating that the effects of metformin therapy on ALT is via its effects on weight.

UR - http://www.scopus.com/inward/record.url?scp=77956095381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956095381&partnerID=8YFLogxK

U2 - 10.1038/oby.2010.21

DO - 10.1038/oby.2010.21

M3 - Article

C2 - 20186137

AN - SCOPUS:77956095381

VL - 18

SP - 1762

EP - 1767

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 9

ER -